EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Modification of tumor cell kill by anesthetics






British Journal of Cancer 41(SUPPL 4): 311

Modification of tumor cell kill by anesthetics



Accession: 028727541



Related references

Peacock, J.H.; Stephens, T.C., 1978: Influence of anesthetics on tumor cell kill and re population in b 16 melanoma treated with melphalan. The influence of anesthetics on the in vivo response of mouse B16 melanoma to melphalan was studied using an in vitro cell survival assay. Three anesthetics were used, Saffan (Althesin) Sagatal (Nembutal) and Hypnorm. When Saffan was administered...

Henderson B.W.; Fingar V.H., 1989: Oxygen limitation of direct tumor cell kill during photodynamic treatment of a murine tumor model. The relationship between levels of in vivo accumulated photosensitizer (Photofrin II), photodynamic cell inactivation upon in vitro or in vivo illumination, and changing tumor oxygenation was studied in the radiation-induced fibrosarcoma (RIF) mou...

Sirotnak, F.M.; Donsbach, R.C.; Dorick, D.M.; Moccio, D.M., 1976: Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high-dose methotrexate in murine tumor models. In Sarcoma 180 and L1210 ascites tumor models, the initial rate of methotrexate accumulation in tumor cells in the peritoneal cavity and in small intestine (intracellularly) after s.c. doses up to 800 mg/kg, showed saturation kinetics. These resul...

Modzelewski, R.A.; Chang, M.J.; Phillips, S.L.; Johnson, C.S., 1997: Enhancement of cisplatin-mediated tumor cell kill by cytokine induction of nitric oxide production from tumor-derived endothelial cells. Proceedings of the American Association for Cancer Research Annual Meeting 38(0): 312

Das U.N., 1990: Selective enhancement of free radicals by cis unsaturated fatty acids in tumor cells as a strategy to kill tumor cell in vitro and in vivo. Reddy, C C , G A Hamilton And K M Madyastha (Ed ) Biological Oxidation Systems, Vols 1 And 2; Symposium, Bangalore, India, October 22-26, 1989 Xxi+534p (Vol 1); Xx+535p (Vol 2) Academic Press, Inc : San Diego, California, Usa; London, England, Uk Illus 607-624

Wallen, C.A.; Moore, S.K.; Wheeler, K.T., 1992: Modification of alkylating agent induced cell kill by 2-nitroimidazoles in unclamped and clamped SC 9L tumors. Enhanced cell kill has been observed when experimental tumors were treated with alkylating agents in combination with 2-nitroimidazoles (2-NI). In this study, modification of the cell kill induced by cyclophosphamide (CY) and an analog, ifosfamide...

Mastbergen, S.C.; Duivenvoorden, I.; Versteegh, R.T.; Geldof, A.A., 2000: Cell cycle arrest and clonogenic tumor cell kill by divergent chemotherapeutic drugs. Background: Regulators of cell cycle phase transitions could be important targets for cancer treatment using cytostatic chemotherapy. Therefore, the extent of cell cycle arrest induced by different cytostatic agents has to be correlated with ultim...

Weisenthal, L.M., 1994: Clinical correlations for cell culture assays based on the concept of total tumor cell kill. Contributions to Gynecology and Obstetrics 19: 82-90

PadrĂ³n, J.M.; van Moorsel, C.J.; Bergman, A.M.; Smitskamp-Wilms, E.; van der Wilt, C.L.; Peters, G.J., 1999: Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures. Both gemcitabine (2',2'-difluorodeoxycytidine, dFdC) and cisplatin (cis-diammine-dichloroplatinum) have significant anticancer activity against ovarian, head and neck, and non-small cell lung cancer (NSCLC). dFdC can be incorporated into...

Gulbins, E.; Kolesnick, R.N., 2013: It takes a CAD to kill a tumor cell with a LMP. Cancer cells display lysosome hypertrophy, secreting lysosomal hydrolases for tumor progression. Hypertrophy renders lysosomes fragile, increasing lysosomal membrane permeabilization (LMP) tendency. In this issue of Cancer Cell, Petersen and colle...